ProCE Banner Activity

Cevostamab: Novel FcRH5 x CD3 Bispecific Antibody in Patients With R/R MM

Slideset Download
Conference Coverage

Novel bispecific antibody targeting FcRH5, cevostamab, active and tolerable in heavily pretreated patients with R/R MM

Released: December 09, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology